A Novel Camptothecin Derivative Incorporated in Nano-Carrier Induced Distinguished Improvement in Solubility, Stability and Anti-tumor Activity Both In Vitro and In Vivo
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
An oil/water nanoemulsion was developed in the present study to enhance the solubility, stability and anti-tumor activity of a novel 10-methoxy-9-nitrocamptothecin (MONCPT).
Materials and Methods
MONCPT nanoemulsion was prepared using Lipoid E80 and cremophor EL as main emulsifiers by microfluidization. The droplet size of the nanoemulsion was measured by dynamic light scattering. In vitro drug release was monitored by membrane dialysis. Kinetics of MONCPT transformed into carboxylic salt was performed in phosphate buffer at different pH. Hemolysis of MONCPT nanoemulsion was conducted in rabbit erythrocytes. Solubilization character of MONCPT in nanoemulsion was experimented using Nile red as a solvatochromic probe. In vitro cytotoxicity of the nanoemulsion was measured in A549 and S180 cells using Sulforhodamine B protein stain method, and suppression rate of tumor growth was investigated in S180-bearing mice. The cell cycle effects of MONCPT nanoemulsion on S180 cells were analyzed by flow cytometry. Distribution of the nanoemulsion in A549 cells and S180-bearing mice were also investigated by fluorescence image.
MONCPT is incorporated in the nanoemulsion in form of lactone with concentration of 489 µg/ml, more than 200 folds higher than that in water. Experiments using Nile red as a solvatochromic probe indicated that more MONCPT might be located in the interfacial surfactant layer of the nanoemulsion than that in discrete oil droplet or continuous aqueous phase. Nanoemulsion could release MONCPT in a sustained way, and it was further shown to notably postpone the hydrolysis of MONCPT with longer hydrolysis half-life time (11.38 h) in nanoemulsion at pH 7.4 than that of MONCPT solution (4.03 h). No obvious hemolysis was caused by MOCPT nanoemulsion in rabbit erythrocytes. MONCPT nanoemulsion showed a marked increase in cytotoxic activity, 23.6 folds and 28.6 folds in S180 cells and A549 cells respectively via arresting the cell at G2 phase, compared to that induced by MONCPT injection. It correlated well to the in vivo anti-tumor activity of MONCPT nanoemulsion with suppression rate of 93.6%, while that of MONCPT injection was only 24.2% at the same dosage. Moreover, nanoemulsion exhibited enhanced capability of delivering drug into malignant cell’s nucleus in vitro and induced drug accumulation in tumor in S180-bearing mice using in vivo imaging.
The nanoemulsion prepared exhibited an improved MONCPT solubility, stability and anti-tumor activity, providing a promising carrier for cancer chemotherapy using MONCPT.
- C. H. Takimoto, J. Wright, and S. G. Arbuck. Clinical applications of the camptothecins. Biochim. Biophys. Acta. 1400:107–119 (1998).
- O. Lavergne, and D. C. Bigg. The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan. Bull. Cancer. 12:51–58 (1998).
- U. Vanhoefer, W. Achterrath, S. Cao, S. Seeber, and Y. M. Rustum. Irinotecan in the treatment of colorectal cancer: clinical overview. J. Clin. Oncol. 19:1501–1518 (2001).
- Z. S. Cao, K. Armstrong, M. Shaw, E. Petry, and N. Harris. Nitration of camptothecin with various inorganic nitrate salts in concentrated sulfuric acid: a new preparation of anticancer drug 9-nitrocamptothecin. Synthesis. 12:1724–1730 (1998). doi:10.1055/s-1998-2207. CrossRef
- M. C. Wani, A. W. Nicholas, and M. E. Wall. Plant antitumor agents .23. Synthesis and antileukemic activity of camptothecin analogues. J. Med. Chem. 29:2858–2863 (1986). doi:10.1021/jm00161a035. CrossRef
- M. Gao, K. D. Miller, G. W. Sledgeb, and Q. H. Zheng. Radiosynthesis of carbon-11-labeled camptothecin derivatives as potential positron emission tomography tracers for imaging of topoisomerase I in cancers. Bioorg. Med. Chem. Lett. 15:3865–3869 (2005). doi:10.1016/j.bmcl.2005.05.108. CrossRef
- X. C. Yang, P. H. Luo, B. Yang, and Q. J. He. Antiangiogenesis response of endothelial cells to the antitumour drug 10-methoxy-9-nitrocamptothecin. Pharmacol. Res. 54:334–340 (2006). doi:10.1016/j.phrs.2006.06.001. CrossRef
- P. H. Luo, Q. J. He, X. G. He, Y. Z. Hu, W. Lu, Y. Y. Cheng, and B. Yang. Potent antitumor activity of 10-methoxy-9-nitrocamptothecin. Mol. Cancer. Ther. 54:962–968 (2006). doi:10.1158/1535-7163.MCT-05-0385. CrossRef
- C. J. Thomas, N. J. Rahier, and S. M. Hecht. Camptothecin: current perspectives. Bioorg. Med. Chem. 12:1585–1604 (2004). doi:10.1016/j.bmc.2003.11.036. CrossRef
- J. J. Zhou, J. Liu, and B. Xu. Relationship between lactone ring forms of HCPT and their antitumor activities. Acta. Pharmacol. Sin. 22:827–830 (2001).
- R. P. Hertzberg, M. J. Caranfa, K. G. Holden, D. R. Jakas, G. Gallagher, M. R. Mattern, S. M. Mong, J. O. Bartus, R. K. Johnson, and W. D. Kingsbury. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. 32:715–720 (1989). doi:10.1021/jm00123a038. CrossRef
- S. Kawakami, F. Yamashita, and M. Hasida. Disposition characteristics of emulsions and incorporated drugs after systemic or local injection. Adv. Drug Deliv. Rev. 45:77–88 (2000). doi:10.1016/S0169-409X(00)00102-2. CrossRef
- P. P. Constantinides, K. J. Lambert, A. K. Tustian, B. Schneider, S. Lalji, W. Ma, B. Wentzel, D. Kessler, D. Worah, and S. C. Quay. Formulation development and antitumor activity of filter-sterilizable emulsion of paclitaxel. Pharm. Res. 17:175–182 (2000). doi:10.1023/A:1007565230130. CrossRef
- J. Rossi, S. Giasson, M. N. Khalid, P. Delmas, C. Allen, and J. C. Leroux. Long-circulation poly (ethylene glycol)-coated emulsions to target solid tumors. Eur. J. Pharm. Biopharm. 67:329–338 (2007). doi:10.1016/j.ejpb.2007.03.016. CrossRef
- K. Zurowska-Pryczkowska, M. Sznitowska, and S. Janicki. Studies on the effect of pilocarplne incorporation into a submicron emulsion on the stability of the drug and the vehicle. Eur. J. Pharm. Biopharm. 47:255–260 (1999). doi:10.1016/S0939-6411(98)00098-8. CrossRef
- M. J. Lawrence, and G. D. Rees. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 45:89–121 (2000). doi:10.1016/S0169-409X(00)00103-4. CrossRef
- O. Sonneville-Aubrun, J. T. Simonnet, and F. l’Alloret. Nanoemulsions: a new vehicle for skincare products. Adv. Colloid Interface Sci. 108–109:145–149 (2004). doi:10.1016/j.cis.2003.10.026. CrossRef
- L. A. Pires, R. Hegg, C. J. Valduga, S. R. Graziani, D. G. Rodrigues, and R. C. Maranhao. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemother Pharmacol., in press (2008) http://www.springerlink.com/content/t1452120506h7327/.
- D. Attivi. Formulation of insulin-loaded polymeric nanoparticles using response surface methodology. Drug DeV. Ind. Pharm. 31:179–189 (2005). doi:10.1081/DDC-200047802. CrossRef
- L. Copolovici, and U. Niinemets. Salting-in and salting-out effects of ionic and neutral osmotica on limonene and linalool Henry’s law constants and octanol/water partition coefficients. Chemosphere. 69:621–629 (2007). doi:10.1016/j.chemosphere.2007.02.066. CrossRef
- M. Y. Levy, and S. Benita. Drug release from submicronized o/w emulsion: new in vitro kinetic evaluation model. Int. J. Pharm. 66:29–37 (1990). doi:10.1016/0378-5173(90)90381-D. CrossRef
- M. B. Moshe, S. Magdassi, Y. Cohen, and L. Avram. Structure of microemulsions with Gemini surfactant studied by solvatochromic probe and diffusion NMR. J. Colloid Interface Sci. 276:221–226 (2004). doi:10.1016/j.jcis.2004.03.015. CrossRef
- P. Skehan, D. Scudiero, R. Storeng, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenney, and M. R. Boyd. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Nat. Cancer Inst. 82:1107–1112 (1990). doi:10.1093/jnci/82.13.1107. CrossRef
- S. S. Rane, and B. D. Anderson. What determines drug solubility in lipid vehicles: is it predictable. Adv. Drug Del. Rev. 60:638–656 (2008). doi:10.1016/j.addr.2007.10.015. CrossRef
- C. Malcolmson, C. Satra, S. Kantaria, A. Sidhu, and M. J. Lawrence. Effect of oil on the level of solubilization of testosterone propionate into nonionic oil-in-water microemulsions. J. Pharm. Sci. 87:109–116 (1998). doi:10.1021/js9700863. CrossRef
- H. Kunieda, N. Masuda, and K. Tsubone. Comparison between phase behavior of anionic dimeric (Gemini-Type) and monomeric surfactants in water and water-oil. Langmuir. 16:6438–6444 (2000). doi:10.1021/la0001068. CrossRef
- F. Liu, and D. Liu. Long-circulating emulsions (oil-in-water) as carriers for lipophilic drugs. Pharm. Res. 12:1060–1064 (1995). doi:10.1023/A:1016274801930. CrossRef
- D. F. Zhong, K. Li, J. H. Xu, Y. Du, and Y. F. Zhang. Pharmacokinetics of 9-nitro-20(S)-camptothecin in rats. Acta Pharmacol. Sin. 24:256–262 (2003).
- P. K. Ghosh, and R. S. R. Murthy. Microemulsions: a potential drug delivery system. Curr. Drug Deliv. 3:167–180 (2006). doi:10.2174/156720106776359168. CrossRef
- J. B. Tagne, S. Kakumanu, D. Ortiz, T. Shea, and R. J. Nicolosi. A nanoemulsion formulation of tamoxifen increases its efficacy in a breast cancer cell line. Mol. Pharm. 5:280–286 (2008). doi:10.1021/mp700091j. CrossRef
- T. Masuda, H. Akita, T. Nishio, K. Niikura, K. Kogure, K. Ijiro, and H. Harashima. Development of lipid particles targeted via sugar-lipid conjugates as novel nuclear gene delivery system. Biomaterials. 29:709–723 (2008). doi:10.1016/j.biomaterials.2007.09.039. CrossRef
- W. Junping, K. Takayama, T. Nagai, and Y. Maitani. Pharmacokinetics and antitumor effects of vincristine carried by microemulsions composed of PEG-lipid, oleic acid, vitamin E and cholesterol. Int. J. Pharm. 251:13–21 (2003). doi:10.1016/S0378-5173(02)00580-X. CrossRef
- B. A. Teicher. Molecular targets and cancer therapeutics: discovery, development and clinical validation. Drug Resist Updat. 3:67–73 (2000). doi:10.1054/drup.2000.0123. CrossRef
- A Novel Camptothecin Derivative Incorporated in Nano-Carrier Induced Distinguished Improvement in Solubility, Stability and Anti-tumor Activity Both In Vitro and In Vivo
Volume 26, Issue 4 , pp 926-935
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- 10-Methoxy-9-nitrocamptothecin (MONCPT)
- nile red
- Industry Sectors
- Author Affiliations
- 1. Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
- 2. Institute of Pharmacology & Toxicology and Biochemical Pharmacy, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China
- 3. 2nd Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
- 4. Institute of Material Medica, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China